Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: REPL stock price vs ANIP: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ANIP's multiple
Needs Revenue / share, ANIP P/S.
Implied fair value · at REPL's multiple
Needs REPL P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
REPLIMUNE GROUP, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
ANI PHARMACEUTICALS, INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
REPL vs AMGN
INCYTE CORP
REPL vs INCY
Blueprint Medicines Corp
REPL vs BPMC
Adaptive Biotechnologies Corp
REPL vs ADPT
SUPERNUS PHARMACEUTICALS, INC.
REPL vs SUPN
PERRIGO Co plc
REPL vs PRGO
Viatris Inc
REPL vs VTRS
Organon & Co.
REPL vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
REPL vs TEVA
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe REPL can materially improve profitability and reverse its weak quality score from 1/9, then consider the stock for a speculative position because the current price is inside its historical band and the valuation appears low versus a profitable ANIP; otherwise, ANIP's stronger earnings and growth profile make the relative case more defensible.
REPL is trading at $11.58, inside its historical band of $10.42 to $12.74, so the stock is not obviously dislocated relative to its own recent range. However, relative valuation is hard to frame cleanly because REPL lacks revenue-based multiples and has negative earnings and EBITDA, while ANIP trades at 25.9x P/E, 2.2x P/S, and 9.0x EV/EBITDA on a profitable, revenue-generating base.
Supporting Metrics
